Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lifeng Geng is active.

Publication


Featured researches published by Lifeng Geng.


Journal of Medicinal Chemistry | 2009

Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents

Kenneth He Huang; James Marvin Veal; R. Patrick Fadden; John W. Rice; Jeron Eaves; Jon-Paul Strachan; Amy F. Barabasz; Briana Foley; Thomas E. Barta; Wei Ma; Melanie Silinski; Mei Hu; Jeffrey M. Partridge; Anisa Scott; Laura G. Dubois; Tiffany A. Freed; Paul M. Steed; Andy J. Ommen; Emilie D. Smith; Philip F. Hughes; Angela R. Woodward; Gunnar J. Hanson; W. Stephen Mccall; Christopher John Markworth; Lindsay Hinkley; Matthew Jenks; Lifeng Geng; Meredith Lewis; James Otto; Bert Pronk

A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compound library. These indol-4-one and indazol-4-one derived 2-aminobenzamides showed strong binding affinity to Hsp90, and optimized analogues exhibited nanomolar antiproliferative activity across multiple cancer cell lines. Heat shock protein 70 (Hsp70) induction and specific client protein degradation in cells on treatment with the inhibitors supported Hsp90 inhibition as the mechanism of action. Computational chemistry and X-ray crystallographic analysis of selected member compounds clearly defined the protein-inhibitor interaction and assisted the design of analogues. 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans-4-hydroxycyclohexyl)amino]benzamide (SNX-2112, 9) was identified as highly selective and potent (IC(50) Her2 = 11 nM, HT-29 = 3 nM); its prodrug amino-acetic acid 4-[2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-phenylamino]-cyclohexyl ester methanesulfonate (SNX-5422, 10) was orally bioavailable and efficacious in a broad range of xenograft tumor models (e.g. 67% growth delay in a HT-29 model) and is now in multiple phase I clinical trials.


Bioorganic & Medicinal Chemistry Letters | 2008

Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90

Thomas E. Barta; James M. Veal; John W. Rice; Jeffrey M. Partridge; R. Patrick Fadden; Wei Ma; Matthew Jenks; Lifeng Geng; Gunnar J. Hanson; Kenneth He Huang; Amy F. Barabasz; Briana Foley; James Otto; Steven E. Hall

Hsp90 maintains the conformational stability of multiple proteins implicated in oncogenesis and has emerged as a target for chemotherapy. We report here the discovery of a novel small molecule scaffold that inhibits Hsp90. X-ray data show that the scaffold binds competitively at the ATP site on Hsp90. Cellular proliferation and client assays demonstrate that members of the series are able to inhibit Hsp90 at nanomolar concentrations.


Bioorganic & Medicinal Chemistry Letters | 2009

Novel carbazole and acyl-indole antimitotics

Thomas E. Barta; Amy F. Barabasz; Briana Foley; Lifeng Geng; Gunnar J. Hanson; Matthew Jenks; Wei Ma; John W. Rice; James M. Veal

In the course of our Heat Shock 90 program, certain carbazole compounds were identified which had an off-target antiproliferative activity. To understand the off-target activity, we studied one analog with strong activity. We discovered that it had an effect on tubulin polymerization kinetics and was competitive with colchicine. Additional analogs were made, and a number of potent compounds were identified.


Archive | 1998

3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors

Ashok Anantanarayan; Michael Clare; Lifeng Geng; Gunnar J. Hanson; Richard A. Partis; Michael A. Stealey; Richard M. Weier


Archive | 2007

Benzene, pyridine, and pyridazine derivatives

Kenneth He Huang; Jeron Eaves; Gunnar J. Hanson; James M. Veal; Thomas E. Barta; Lifeng Geng; Lindsay Hinkley


Journal of Medicinal Chemistry | 2007

Synthesis, Crystal Structure, and Activity of Pyrazole-Based Inhibitors of p38 Kinase

Matthew J. Graneto; Ravi G. Kurumbail; Michael L. Vazquez; Huey-Sheng Shieh; Jennifer L. Pawlitz; Jennifer M. Williams; William C. Stallings; Lifeng Geng; Ashok S. Naraian; Francis J. Koszyk; Michael A. Stealey; Xiangdong D. Xu; Richard M. Weier; Gunnar J. Hanson; Robert J. Mourey; Robert P. Compton; Stephen J. Mnich; Gary D. Anderson; Joseph B. Monahan; Rajesh Devraj


Archive | 2008

Pyridine, and pyridazine derivatives

Jeron Eaves; James Marvin Veal; Thomas E. Barta; Lifeng Geng; Lindsay Hinkley


Cancer Research | 2006

A novel, orally active, small molecule Hsp90 inhibitor.

Patrick Fadden; Amy F. Barabasz; Tom Barta; Jeron Eaves; Briana Foley; Lifeng Geng; Steven E. Hall; Gunnar J. Hanson; He Huang; James Otto; Bert Pronk; John R. Rice; James M. Veal


Archive | 2005

PIRAZOLES SUBSTITUIDOS COMO INIBIDORES DE P38 QUINASE

Clare Michael; Metz Suzanne; Talley John Jeffrey; Devraj Rajesh; Hanson Gunnar J; Partis Richard A; Rao Shashidhar N; Yu Yi; Stealey Michael A; Graneto Matthew J; Weier Richard M; Khanna Ish K; Hanau Cathleen E; Hartmann Susan J; Xu Xiangdong; Vazquez Michael L; Ashok Anantanarayan; Paul W. Collins; Crich Joyce Z; Daniel L. Flynn; Lifeng Geng; Michael Hepperle; He Huang; Koszyk Francis J; Shuyuan Liao; Perry Thao D; Raj Selness Shaun; South Michael S; Baldus John E; Jerome Kevin D


Archive | 2002

Composes substitues de sulfamide benzene de pyrazolyl destines au traitement des inflammations

Lifeng Geng; Michael Clare; Gunnar J. Hanson; He Huang; Donna M. Iula; Shuyuan Lia; Michael A. Stealey; Suzanne Metz; Michael L. Vazquez; Richard M. Weier

Collaboration


Dive into the Lifeng Geng's collaboration.

Researchain Logo
Decentralizing Knowledge